5 years of biosimilars in the US: what have we learned?Biologics have created revolutionary treatment options that have transformed the care journey for hundreds of millions of patients Share X5 years of biosimilars in the US: what have we learned?https://pharmaphorum.com/views-analysis-market-access/5-years-of-biosimilars-in-the-us-what-have-we-learned/
Who could replace Sir Andrew Dillon at NICE?With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the Share XWho could replace Sir Andrew Dillon at NICE?https://pharmaphorum.com/views-and-analysis/who-could-replace-sir-andrew-dillon-at-nice/
